the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Stakeholder Opinions: Physician perception of biologics in Autoimmune Disease - Targeted detailing is the key to success

Published by Datamonitor Contact us : +1-860-674-8796
Published 2009/03 Content info 137 pages
Product code DC83172
Price From  US $ 3800 Order/Price list
US $ 3800 PDF by E-mail (Single User License)
US $ 9500 PDF by E-mail (Global Site License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Abstract

Introduction

Factors influencing a prescribing decision can diverge from clinical facts. In the highly competitive autoimmune area, misconceptions and physician habits can result in loss of sales. Targeted detailing of specialist physicians, differentiating by indications is the key to success. Datamonitor has surveyed gastroenterologists, rheumatologists and dermatologists on attribute and brand perceptions.

Scope of this research

  • Opinion from 540 physicians including rheumatologists, dermatologists and gastroenterologists is included
  • Physicians and opinion leaders across the seven major markets of the US, Japan, France, Germany, Spain, Italy and the UK
  • Analysis of the extent to which certain factors affect physician prescribing, with comparison across each specialty
  • Analysis of the opinion dynamics for the key brands used across prominent autoimmune diseases

Research and analysis highlights

Efficacy and safety factors will always be any physician' s main consideration, drawing an average of 62% of the weighting by importance when prescribing a biologic therapy. Actemra' s positive perception from rheumatologists, despite known side-effects, exemplifies the importance of informing physicians about issues, rather than masking them.

New TNF inhibitors in autoimmune disease battle against ' me-too' status and the strong positive opinion of the existing three products in the category. Humira leads the group with a total score 16% above the average. Newcomer anti-TNF options Simponi (golimumab) and Cimzia (certolizumab) are not well perceived by EU prescribing rheumatologists.

Dermatologists' exhibit cynicism towards biologic therapies, scoring all brands lower than other physician types, less surprising when considering the nature of most psoriasis therapies. However, Centocor' s Stelara (ustekinumab) is highly anticipated with dermatologists scoring it 40% above average in terms of predicted efficacy.

Key reasons to purchase this research

  • Target physicians more efficiently by understanding the differences in brand perception between physician specialties
  • Tailor your marketing message to the attributes most important to prescribing physicians
  • Assess the regional dynamics of physician perception in autoimmune disease across the seven major markets
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.